Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors

JL Woodhead, WJ Brock, SE Roth… - Toxicological …, 2017 - academic.oup.com
Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries
for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD…

Editor's highlight: Candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach

M Mosedale, Y Kim, WJ Brock, SE Roth… - Toxicological …, 2017 - academic.oup.com
Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of
Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for …

[HTML][HTML] Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal …

…, VE Torres, H Li, W Wang, ME Hoke, SE Roth… - American Journal of …, 2023 - Elsevier
Rationale & Objective Tolvaptan is associated with risk of drug-induced liver injury when
used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was …

miR-122 release in exosomes precedes overt tolvaptan-induced necrosis in a primary human hepatocyte micropatterned coculture model

…, SR Khetani, J Lu, WJ Brock, SE Roth… - Toxicological …, 2018 - academic.oup.com
Idiosyncratic drug-induced liver injury (IDILI) is thought to often result from an adaptive immune
attack on the liver. However, it has been proposed that the cascade of events culminating …

Next‐generation DILI biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development

SE Roth, MI Avigan, D Bourdet, D Brott… - Clinical …, 2020 - Wiley Online Library
The diagnosis and management of drug‐induced liver injury ( DILI ) remains a challenge in
clinical trials in drug development. The qualification of emerging biomarkers capable of …

Bile acids as potential biomarkers to assess liver impairment in polycystic kidney disease

…, JR Slizgi, M Su, W Jia, SE Roth… - … journal of toxicology, 2018 - journals.sagepub.com
Polycystic kidney disease is characterized by the progressive development of kidney cysts
and declining renal function with frequent development of cysts in other organs including the …

Altered expression and function of hepatic transporters in a rodent model of polycystic kidney disease

J Bezençon, JJ Beaudoin, K Ito, D Fu, SE Roth… - Drug Metabolism and …, 2019 - ASPET
Autosomal dominant polycystic kidney disease (ADPKD) is a common form of inherited
polycystic kidney disease (PKD) and is a leading cause of kidney failure. Fluid-filled cysts …

Altered hepatobiliary disposition of tolvaptan and selected tolvaptan metabolites in a rodent model of polycystic kidney disease

…, J Bezençon, Y Cao, K Mizuno, SE Roth… - Drug Metabolism and …, 2019 - ASPET
Tolvaptan, a vasopressin V 2 -receptor antagonist, has demonstrated efficacy in slowing
kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD)…

Simultaneous quantitation of delamanid (OPC-67683) and its eight metabolites in human plasma using UHPLC–MS/MS

…, B Johnston, S Carter, J Brisson, SE Roth - … of Chromatography B, 2015 - Elsevier
Delamanid (OPC-67683) is a novel nitro-dihydroimidazo-oxazole derivative that is being
developed by Otsuka Pharmaceutical Co., Ltd., Japan (referred to as Otsuka hereafter) for the …

Peptide-mediated delivery of siRNA via noncovalent complexes and covalent conjugates

…, L Chen, Y Chen, K Cui, KW Farber, SE Roth… - … Biology Using Peptides …, 2006 - Springer
Improving the intracellular delivery of synthetic oligonucleotides and their analogs is an
important goal in the development of small interfering RNA (siRNA) therapeutics for affecting …